'Fighter drugs' and their misuse by armed non-state actors represent an emerging dimension of transnational security threats.

Q. 'Fighter drugs' and their misuse by armed non-state actors represent an emerging dimension of transnational security threats. (15 marks, 250-350 words)

'Fighter drugs' are synthetic opioids and stimulants — Tramadol being the archetype, so named for its reported use by armed fighters to blunt fatigue, pain and fear — that have migrated from pharmacies to conflict theatres. Their misuse marks a genuine shift in transnational security, though the threat is one of diversion, not of new narcotics.

Why they attract armed non-state actors - Unlike heroin or cocaine, they are legally manufactured medicines, cheap, stable and available in bulk — combat utility without cultivation or clandestine synthesis. - Bulk sale doubles as conflict financing, tying organised crime to insurgent economies — the classic narco-terror nexus. - Conflict-zone demand pulls consignments toward ungoverned spaces such as Libya, routed through weak-enforcement West African transit states like Guinea-Bissau [1].

India's exposure as a pharmaceutical hub - India's scale as a formulations exporter makes legitimate EXIM channels the preferred cover. Under "Operation Vajra" (July 2026), the Central Bureau of Narcotics seized 12 crore Tramadol tablets (~30 metric tons) from a Delhi warehouse, with arrests in Bengaluru and Kochi [1]. - Misdeclaration of destination is the core modus operandi — the consignment declared for Guinea-Bissau was intended for diversion to Libya [1]. - The domestic flank is clandestine manufacture: CBN has unearthed a Tramadol unit at Bawana operating as a honey plant, its tablets branded as ayurvedic medicine [3].

The regulatory and enforcement response - Tramadol was notified a psychotropic substance by S.O. 1761(E) of 2018, restricting its export under Section 8(c), NDPS Act, 1985 [2]. - Detection now depends on multi-agency and cross-border verification — CBN worked with DRI and, critically, with the INCB and Guinea-Bissau's competent authority to expose the false destination [1].

The threat is therefore less about a new drug than about the porosity of legitimate trade. India should pair its strong statutory base with end-use verification and real-time destination authentication for controlled exports, while deepening INCB-anchored cooperation. Guarding the integrity of the "pharmacy of the world" is simultaneously a public-health, trade-credibility and security imperative.

(~325 words)

Sources: 1. PIB — CBN India thwarts illegal trafficking of 12 crore Tramadol Hydrochloride "fighter drug" tablets under "Operation Vajra" — seizure quantum and location, arrests, Guinea-Bissau/Libya diversion, DRI and INCB coordination 2. Gazette of India, Notification S.O. 1761(E) dated 26.04.2018, NDPS Act, 1985 (India Code) — Tramadol notified as a psychotropic substance; export restricted under Section 8(c) 3. PIB — Central Bureau of Narcotics busts illegal drug manufacturing factory in Delhi (2022) — clandestine Tramadol unit at Bawana disguised as a honey plant, tablets branded as ayurvedic medicine